Chronic pruritus L20 L40 L43 L29.8
Conditions
Interventions
Group 1: arm 1: patients with chronic-inflammatory skin diseases with chronic pruritus.
Description:
Our key objective is the characterization of known (IL-31, NGF, TSLP) and the identification of no
Sponsors
Universitätsklinik für Dermatologie und Allergologie, Klinikum Oldenburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with chronic pruritus (due to lichen planus, psoriasis and atopic dermatitis); minimum age 18 years
Exclusion criteria
Exclusion criteria: Patients who cannot complete the questionnaires due to physical or psychiatric diseases or an insufficient understanding of the German language. Patients taking antipruritic drugs. Patients with an infection at the potential biopsy area. Patients who received anti-inflammatory therapy within the last two weeks and pregnant or breast-feeding women are excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| expression profiles of pruritic mediators (immunohistochemistry and immunofluorescence, ELISA, Western Blot) gene expression profiles (qPCR, RNA sequencing) Patient questionnaires: NeuroDerm questionnaire, 5PLQ, SF12, Beck´s Depression Inventory (BDI), Trait anxiety inventory (STAI-T), Self-Administered Comorbidity Questionnaire (SCQ), Brief Pain Inventory (BPI), Pain Catastrophizing Scale, Neuropathic pain symptom inventory (NPSI) | — |
Secondary
| Measure | Time frame |
|---|---|
| better understanding of the pruritus pathways | — |
Countries
Germany
Contacts
Public ContactTobias Weihrauch
Abteilung für Experimentelle Allergologie und Immundermatologie
Outcome results
None listed